miR-30a suppresses breast cancer cell proliferation and migration by targeting Eya2
•miR-30a represses Eya2 expression by binding to the 3′-untranslated region of Eya2.•The miR-30a/EYA2 axis regulates breast cancer cell proliferation and migration.•The miR-30a/EYA2 axis modulates G1/S cell cycle progression.•The miR-30a/EYA2 axis is dysregulated in breast cancer patients. Eye absen...
Gespeichert in:
Veröffentlicht in: | Biochemical and biophysical research communications 2014-03, Vol.445 (2), p.314-319 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | •miR-30a represses Eya2 expression by binding to the 3′-untranslated region of Eya2.•The miR-30a/EYA2 axis regulates breast cancer cell proliferation and migration.•The miR-30a/EYA2 axis modulates G1/S cell cycle progression.•The miR-30a/EYA2 axis is dysregulated in breast cancer patients.
Eye absent (Eya) proteins are involved in cell fate determination in a broad spectrum of cells and tissues. Aberrant expression of Eya2 has been documented in a variety of cancers and correlates with clinical outcome. However, whether microRNAs (miRNAs) can regulate Eya2 expression remains unknown. Here, we show that miR-30a represses Eya2 expression by binding to the 3′-untranslated region of Eya2. Overexpression of Eya2 in miR-30a-transfected breast cancer cells effectively rescued the inhibition of cell proliferation and migration caused by miR-30a. Knockdown of Eya2 by small-interfering RNA (siRNA) in breast cancer cells mimicked the effect induced by miR-30a and abolished the ability of miR-30a to regulate breast cancer cell proliferation and migration. The miR-30a/Eya2 axis could regulate G1/S cell cycle progression, accompanied by the modulation of expression of cell cycle-related proteins, including cyclin A, cyclin D1, cyclin E, and c-Myc. Moreover, miR-30a expression was downregulated in breast cancer patients, and negatively correlated with Eya2, which was upregulated in breast cancer patients. These data suggest that the miR-30a/Eya2 axis may play an important role in breast cancer development and progression and that miR-30a activation or Eya2 inhibition may be a useful strategy for cancer treatment. |
---|---|
ISSN: | 0006-291X 1090-2104 |
DOI: | 10.1016/j.bbrc.2014.01.174 |